In this part two series, participants give their opinions on the lasting effects of the pandemic. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.
The pandemic flipped the switch on telehealth and at-home care, and the respondents to our annual Pharmacy Survey see them as having staying power. A quarter of the respondents said the increased use of telehealth will be the most important, lasting effect of the pandemic on the U.S. healthcare system and 35% put at-home care of all kinds in that category. Although many experts see the pandemic as accelerating the adoption of value-based payment, only 4% of our respondents ranked that as the pandemic’s most important lasting effect.
Not surprisingly, an increase in research and development on infectious disease got the most votes for the important, lasting effect on the pharmaceutical sector.
The online survey was conducted from April 5 through May 10.
FDA Updates for the Week of May 6: An Approval, a Delay and Two Ad Comm Meetings
May 11th 2024The FDA has approved a liquid mycophenolate to prevent organ rejections but delayed the approval of Moderna’s RSV vaccine. Regulators have set dates for advisory committee meetings for midomafetamine for PTSD and for donanemab in Alzheimer’s disease. Additionally, the agency has set review dates for a subcutaneous Opdivo and a pancreatic/lung cancer therapy.
Read More